NASDAQ: ASND - Ascendis Pharma A/S

Lønnsomhet i seks måneder: -1.57%
Sektor: Healthcare

Kampanjeplan Ascendis Pharma A/S

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Ascendis Pharma A / S, биофармацевтическая компания, разрабатывает терапевтические препараты для неудовлетворенных медицинских потребностей. Компания разрабатывает гормон роста TransCon, который завершил III фазу клинических испытаний дефицита гормона роста. Он также разрабатывает паратиреоидный гормон TransCon для лечения гипопаратиреоза взрослых; и TransCon CNP для ахондроплазии.

flere detaljer
Кроме того, компания разрабатывает доклинические исследования в области онкологии для потенциальных кандидатов на продукты и оценивает системные и локализованные системы доставки с использованием своих технологий TransCon. Компания была зарегистрирована в 2006 году, ее штаб-квартира находится в Хеллерупе, Дания.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2015-01-28
ISIN US04351P1012
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://ascendispharma.com
Цена ао 134.38
Prisendring per dag: +4.02% (129.19)
Prisendring per uke: -4.21% (140.28)
Prisendring per måned: +2.86% (130.64)
Prisendring over 3 måneder: +4.61% (128.46)
Prisendring over seks måneder: -1.57% (136.52)
Prisendring per år: +0.6592% (133.5)
Prisendring over 3 år: +20.91% (111.14)
Prisendring over 5 år: -0.5108% (135.07)
Prisendring over 10 år: 0% (134.38)
Prisendring siden begynnelsen av året: -3.18% (138.79)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 23.87 1
P/BV -43.7 0
P/E 0 0
EV/EBITDA -15.11 0
Total: 2.88

Effektivitet

Navn Betydning Karakter
ROA, % -58.32 0
ROE, % 330.44 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -1.28 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 1894.15 10
Lønnsomhet Ebitda, % 89.45 9
Lønnsomhet EPS, % 74.2 8
Total: 9.4
Flere detaljer

Institusjoner Volum Dele, %
Artisan Partners Limited Partnership 6 9.74
FMR, LLC 5 8.48
Westfield Capital Management Co LP 4 7
Avoro Capital Advisors LLC 4 6.81
Janus Henderson Group PLC 4 6.47
Wellington Management Group, LLP 3 4.72
T. Rowe Price Investment Management, Inc. 3 4.41
Capital International Investors 2 3.76
Franklin Resources, Inc. 2 3.4
Price (T.Rowe) Associates Inc 2 3.06

ETF Dele, % Lønnsomhet for året, % Utbytte, %
Harbor Health Care ETF 15.049 19.98 1.85
Harbor Disruptive Innovation ETF 1.94674 29.05 0.39896
Virtus LifeSci Biotech Products ETF 1.73873 36.79 0.13953
American Century Focused Dynamic Growth ETF 1.00544 51.92 0.16246
Invesco Nasdaq Biotechnology ETF 0.8571 28.58 0.8565
Simplify Health Care ETF 0.85284 27.81 1.00373
Future Tech ETF 0.85005 426.34 0.8416
Principal Healthcare Innovators ETF 0.85005 618.5 0.8416
ProShares UltraShort Nasdaq Biotechnology 0.77 -40.36 1.76
Northern Lights Fund Trust IV 0.69803 37.01 0.49246
ProShares Ultra Nasdaq Biotechnology 0.57302 51.7 0.85651
Putnam Sustainable Future ETF 0.48877 32.87 0.70689
First Trust Nasdaq BuyWrite Income ETF 0.19858 7.27 0.92977
SPDR Portfolio Developed World ex-US ETF 0.02162 3.04 3.28401
PIMCO RAFI Dynamic Multi-Factor International Equity ETF 0.01902 12.12 3.49094
Fidelity Blue Chip Growth ETF 0.01204 41.44 0.54012



Veileder Stillingstittel Betaling Fødselsår
Mr. Jan Moller Mikkelsen President, CEO, Member of Executive Board & Executive Director N/A 1960 (65 år)
Mr. Michael Wolff Jensen L.L.M. Executive VP, Chief Legal Officer & Member of the Executive Board N/A 1971 (54 år)
Mr. Scott T. Smith CFO, Executive VP & Member of Executive Board N/A 1974 (51 år)
Ms. Lotte Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board N/A 1961 (64 år)
Mr. Flemming Steen Jensen Executive Vice President of Product Supply & Quality N/A 1961 (64 år)
Mr. Timothy J. Lee Senior Director of Investor Relations N/A
Dr. Kennett Sprogoe Ph.D. Executive VP and Head of Research & Product Development N/A 1979 (46 år)
Mr. Mads Bodenhoff Senior VP of Finance & Principal Accounting Officer N/A
Dr. Stina Singel M.D., Ph.D. Executive VP & Head of Clinical Development for Oncology N/A 1974 (51 år)
Mr. Joseph Kelly Head of U.S. Commercial of Endocrinology N/A 1969 (56 år)

Adresse: Denmark, Hellerup, Tuborg Boulevard 12 - åpne i Google maps, åpne Yandex-kart
Nettsted: https://ascendispharma.com